ArticleMicrobial cell factories2026
The sugar transporter STP1-driven trophic conversion of Chlamydomonas reinhardtii.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An integrated biomass-to-algae pathway for producing emergency food components from lignocellulosic waste.Current research in food science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChlamydomonas reinhardtii is a versatile model microalga with strong potential for industrial applications in light of its rapid growth, ability to synthesize valuable metabolites, and GRAS status. However, large-scale phototrophic cultivation faces challenges such as self-shading, uneven illumination, as well as the prerequisite of lighting equipment, all of which limit productivity and economic feasibility. Glucose-based heterotrophic cultivation is a scalable alternative, yet C. reinhardtii lacks endogenous glucose transporters, which inherently precludes its glucose uptake.
resultsTo overcome this limitation and expand its trophic flexibility, we engineered C. reinhardtii by introducing the STP1 glucose transporter originating from Arabidopsis thaliana, which confers the ability to uptake glucose. Along with the expression of STP1 in C. reinhardtii, two previously studied glucose transporters were also expressed individually for comparison: GLUT1 from Homo sapiens and HUP1 from Parachlorella kessleri because both are known to enable glucose uptake in C. reinhardtii. Resultingly, all transporter-expressing mutants acquired the ability to uptake glucose. Among tested, the STP1-expressing strain (3S7) exhibited the highest growth under glucose-supplemented heterotrophic conditions despite the marginal difference. The cell number of the 3S7 strain was 3.56 times higher than that of the wild-type (WT) strain, while the cell numbers of the GLUT1- and HUP1-expressing strains were 2.84 and 2.79 times higher, respectively. Dry cell mass analysis confirmed the glucose-based heterotrophic growth of the STP1-expressing strain, showing a 2.03-fold increase compared to the WT, whose weight is the highest among the transformants. Assays using the fluorescent glucose analog 2-NBDG and the non-metabolizable glucose analog 2-DG validated glucose transport into the 3S7 strain and others. The reduced residual glucose in the culture supernatant also supported the 3S7 strain’s primary ability to uptake glucose compared to the other strains, while exhibiting the biomass yield on glucose of 18.9 ± 8.6%.
conclusionsThese results demonstrate that STP1 can be exploited as a promising glucose importer, conferring glucose uptake ability to C. reinhardtii. This study establishes a foundation for increasing its trophic flexibility by broadening its usable organic carbon source, opening up a new opportunity to use the model alga as a cell factory platform for scalable industrial bioprocesses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.